The Value of Rotavirus Vaccination in Europe: A Call for Action

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has pushed many healthcare systems into crisis. High vaccine coverage amongst children reduces emergency room presentations, hospital admissions and deaths due to vaccine-preventable diseases, freeing up healthcare resources i...

Full description

Saved in:
Bibliographic Details
Published in:Infectious diseases and therapy 2023-01, Vol.12 (1), p.9-29
Main Authors: Cohen, Robert, Martinón-Torres, Federico, Posiuniene, Inga, Benninghoff, Bernd, Oh, Kyu-Bin, Poelaert, Dirk
Format: Article
Language:English
Subjects:
Belgium
Commentary
Coronaviruses
COVID-19
Emergency medical services
Epidemics
France
Gastroenteritis
Health care
Hospitalization
Immunization
Infectious Diseases
Internal Medicine
Intestinal obstruction
Medicine
Medicine & Public Health
Pandemics
Pediatrics
Pharmaceutical industry
Prevention
Rotavirus
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Spain
Taxation
United Kingdom
United States
Vaccination
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has pushed many healthcare systems into crisis. High vaccine coverage amongst children reduces emergency room presentations, hospital admissions and deaths due to vaccine-preventable diseases, freeing up healthcare resources including polymerase chain reaction testing for patients with SARS-CoV-2. In Europe, rotavirus gastroenteritis leads to 75,000–150,000 hospitalisations and up to 600,000 medical encounters annually. Nevertheless, in 2022, only 18 countries in Europe (out of 38) have a publicly funded routine universal mass immunisation programme against rotavirus gastroenteritis. Evidence available in the last few years re-emphasises that rotavirus vaccines currently available in Europe are highly effective, preventing up to 96% of rotavirus-related hospitalisations in children less than 1 year of age (potentially 72,000–144,000 hospitalisations Europe-wide). Long-term surveillance indicates that rotavirus vaccination does not result in an overall increase in intussusception. On the contrary, increasing evidence suggests an overall reduction in intussusception in the first 12 months of life when early, high rotavirus vaccine coverage is achieved. Prevention of rotavirus gastroenteritis has marked positive impacts on parental wages and government tax revenue, with benefits extending across the whole economy. In the SARS-CoV-2 pandemic setting there is a new imperative to achieve high levels of paediatric vaccination against vaccine-preventable diseases, including rotavirus gastroenteritis. The introduction of rotavirus universal mass vaccination can be expected to reduce the number of preventable illnesses, hospitalisations and deaths caused by rotavirus gastroenteritis. Reducing vaccine-preventable diseases is particularly urgent at this time when healthcare systems are preoccupied and overwhelmed with SARS-CoV-2. Graphical abstract available for this article. Graphical Abstract
ISSN:2193-8229
2193-6382
DOI:10.1007/s40121-022-00697-7